Results 201 to 210 of about 825,301 (311)

A Comprehensive Evaluation of Hepatitis B Awareness, Knowledge Gaps, Health-Seeking Behaviour, Risk Perceptions, and Vaccination Status Among University Students in Bangladesh: A Cross-Sectional Study. [PDF]

Health Sci Rep
Sakil AA, Hossain MM, Rimon RI, Rahaman H, Nahid RS, Rana MS.   +5 more
europepmc   +1 more source

Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

BMEMat, EarlyView.
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng, Yunfei Sha, Jiongyan Yang, Hongru Yang, Xiao Liang   +4 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Awareness regarding the epidemiology, prevention, treatment, and consequences of viral hepatitis among a predominantly young adult population in the Podillia region (Ukraine): a cross-sectional study. [PDF]

Prev Med Rep
Paliy I, Palii D, Melashchenko S, Voinalovych O, Haiduk O, Ksenchyn O, Chernova I.   +6 more
europepmc   +1 more source

Hepatitis B : are you at risk? [Amharic]

Hepatitis B : are you at risk? [Amharic]AmharicThese sheets have the English translation on the back.cdc/gov/knowhepatitisBFactSheet-HepBAreYouAtRisk_amh-eng ...

core  

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Therapeutic, preventive, and pathogenetic advances in viral hepatitis. [PDF]

Front Cell Infect Microbiol
Jiang H, Zhang YF, Zhang RC, Xing YN.
europepmc   +1 more source

Hepatitis B : are you at risk? [Arabic]

Hepatitis B : are you at risk? [Arabic]ArabicThese sheets have the English translation on the back.cdc/gov/knowhepatitisBFactSheet-HepBAreYouAtRisk_arabic-eng ...

core  

A Practical Guide to Implementing Real‐World Evidence as Primary Basis for Approval and Label Expansion

Clinical Pharmacology &Therapeutics, EarlyView.
In June 2026, the FDA issued a revised draft guidance describing the circumstances in which one adequate and well‐controlled clinical investigation plus confirmatory evidence may satisfy the statutory substantial evidence standard for establishing efficacy and safety. Confirmatory evidence includes real‐world evidence (RWE).
Tracy J. Mayne, Maurice A. Brookhart, Nancy A. Dreyer   +2 more
wiley   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, EarlyView.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source